Imagine a tiny drum made of graphene that can feel the vibrations of a single bacterium. By listening to how these bacteria move, the system can tell if an antibiotic is working almost instantly. Instead of waiting days for bacteria to grow in a lab, this tech identifies the right medicine in under an hour.
Current antibiotic susceptibility tests take 24 hours to several days, leading to incorrect prescriptions and higher mortality rates in acute infections.
A measurement device and consumable cartridges based on graphene biosensors that detect bacterial nanomechanical vibrations.
If you are a lab manager dealing with 24-hour to multi-day diagnostic delays — this project developed a graphene-based biosensor that determines antibiotic susceptibility within one hour. This allows physicians to switch to narrow-spectrum antibiotics faster, potentially saving lives in acute infections like sepsis.
If you are a device maker dealing with the slow growth-rate limitations of current AST systems — this project developed high-volume manufacturing methods for graphene AST cartridges. This enables the production of a high-throughput, cost-effective readout system for clinical use.
If you are a health authority dealing with the threat of 10 million annual deaths by 2050 due to AMR — this project developed a rapid testing platform to promote prudent antibiotic use. This reduces over-prescription and shortens hospital stays across the healthcare system.
Based on available project data, specific pricing is not mentioned, but the project aims to develop a low-cost prototype readout system and cost-effective AST.
The project focuses on building high-volume manufacturing methods and enhancing the throughput of the graphene AST platform.
SoundCell has filed 2 patent applications and plans to file another 4 patents over the project duration.
The project includes establishing a regulatory roadmap to move the technology toward clinical adoption.
The project runs from 2023-11-01 to 2026-10-31, during which prototypes will be placed in hospitals to benchmark against existing platforms.
The project is led by a single SME, SoundCell B.V., a TU Delft spinoff. With a 100% industry ratio and no university or research partners listed in the consortium, the project is heavily focused on commercialization, manufacturing, and market entry rather than basic research.
Contact SoundCell B.V. in the Netherlands regarding their graphene AST platform.
Contact us to explore licensing opportunities for this rapid AST technology.
